Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

To be considered for this study, you would need to be at least 18 years old and have pancreatic cancer that has spread to other parts of your body. Your doctor would need to have confirmed this diagnosis recently, within the last six weeks before you joined the study. It's also important that your body is generally strong enough for treatment; doctors use a simple score (called ECOG 0 or 1) to check this, meaning you are able to do most of your daily activities.

You would also need to have not received any previous cancer treatment for your advanced pancreatic cancer, and your doctors would need to check that your important organs, like your liver, kidneys, and bone marrow, are working well enough. You'd also need to be able to swallow medicines if they are given as tablets.

Some things might mean you can't join the study. For example, if you've had major surgery very recently (in the last 28 days), or if your cancer has spread to your brain and isn't under control. Also, if there are other health conditions that would make it difficult for you to take the study drugs or follow the study plan, you might not be able to participate. Your doctor will discuss all of these points with you carefully.

If you decide to take part in this study, you will first have a number of checks to make sure the study is right for you. If you qualify, you will then be randomly assigned, like flipping a coin, to one of three treatment groups. This means you won't choose which treatment you get. You will either receive the new drug daraxonrasib by itself, daraxonrasib plus standard chemotherapy, or just the standard chemotherapy (gemcitabine and nab-paclitaxel).

Throughout the study, you will have regular visits to the hospital for your treatments, blood tests, scans (like CT scans) to check how the cancer is responding, and to discuss any side effects you might be experiencing. The study drugs may be given as tablets or through a drip (infusion). You'll be closely monitored by the study team. The total length of your participation will depend on how you respond to the treatment and whether you have any side effects, but it will continue as long as the treatment is helping you and is safe to take, with regular follow-up checks after treatment finishes.